Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.

Scientific reports - 15 Mar 2026

Zhang Chi, Cao Senming, Zeng Guineng, Dong Yuhao, Li Hongzhao, Ma Xin, Zhang Xu, Li Zhi, Huang Yan

Abstract excerpt

TP53 is frequently mutated in bladder cancer and is associated with aggressive disease, yet actionable strategies that also improve responses to immune checkpoint blockade remain limited. Here we show that APR-246 (eprenetapopt), a mutant p53–reactivating agent, preferentially reduces viability in TP53-mutant bladder cancer cell lines and that its activity appears to be partially dependent on mutant p53....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Reactive Oxygen Species

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41840064
DOI: 10.1038/s41598-026-44653-8
PMCID: PMC13121771

Genes

TP53
CCL5
CD4
CXCL10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.PMID 41840064Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.Semantic proximity Read ↗

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read ↗

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read ↗

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cellsSemantic proximity Read ↗

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read ↗

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation statusSemantic proximity Read ↗

APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.Semantic proximity Read ↗

Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCTSemantic proximity Read ↗

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read ↗

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.Semantic proximity Read ↗

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Semantic proximity Read ↗

Prima-1 induces apoptosis in bladder cancer cell lines by activating p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.